SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATMENT WITH 5-AZACITIDINE: EXPERIENCE OF A CENTER

被引：0
|
作者：
Busnego, M. T. [1 ]
Sanchez, A. [1 ]
Notario, C. [1 ]
Cabello, A. [1 ]
Oliva, A. [1 ]
Brena, J. [1 ]
Alberich, M. P. [1 ]
Gonzalez, H. [1 ]
Marrero, C. [1 ]
Rios, P. [1 ]
Figueroa, A. [1 ]
Hernanz, N. [1 ]
Rios, M. [1 ]
Leon, A. [1 ]
Hernandez, P. [1 ]
Hillebrand, P. [1 ]
Uribe, L. [1 ]
Mesa, M. C. [1 ]
机构：
[1] Hosp Univ Nuestra Senora Candelaria, Santa Cruz de La Palma, Spain
来源：
HAEMATOLOGICA | 2019年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB-049
引用
收藏
页码：424 / 424
页数：1
相关论文
共 50 条
  • [21] Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia
    Sadashiv, Santhosh K.
    Hilton, Christie
    Khan, Cyrus
    Rossetti, James M.
    Benjamin, Heather L.
    Fazal, Salman
    Sahovic, Entezam
    Shadduck, Richard K.
    Lister, John
    CANCER MEDICINE, 2014, 3 (06): : 1570 - 1578
  • [22] Mutant TET2 Allele Dosage Affects Response to 5-Azacitidine in Acute Myeloid Leukemia
    Stoelzel, Friedrich
    Fordham, Sarah Elizabeth
    Lin, Wei Yu
    Blair, Helen
    Ruhnke, Leo
    Kunadt, Desiree
    Mohr, Brigitte
    Elstob, Claire
    Allsop, Daniel
    Nandana, Devi
    Soura, Emmanouela-Niki
    Park, Catherine
    Fadly, Mohd
    Rahman, Thahira
    Heidenreich, Olaf
    Altmann, Heidi
    Jones, Gail
    Menne, Tobias
    Wobus, Manja
    Jackson, Graham
    Marr, Helen
    Onel, Kenan
    Meggendorfer, Manja
    Haferlach, Torsten
    Bornhauser, Martin
    Allan, James M.
    BLOOD, 2019, 134
  • [23] TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA WITH 5-AZACITIDINE: A CASE SERIES
    Moita, F.
    Thorpe, M.
    Almeida, A.
    HAEMATOLOGICA, 2012, 97 : 588 - 588
  • [24] SINGLE CENTRE SURVIVAL OUTCOMES IN THE TREATMENT OF INTERMEDIATE AND HIGH-RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKAEMIA WITH 5-AZACITIDINE
    Stringer, R.
    Rider, D. T.
    Newman, D. J.
    Grace, D. R.
    HAEMATOLOGICA, 2015, 100 : 725 - 726
  • [25] Azacitidine in adult patients with acute myeloid leukemia
    Schuh, Andre C.
    Doehner, Hartmut
    Pleyer, Lisa
    Seymour, John F.
    Fenaux, Pierre
    Dombret, Herve
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 116 : 159 - 177
  • [26] AZACITIDINE FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIAS: A SINGLE CENTER EXPERIENCE
    Michallet, M.
    Champigneulle, C.
    Sobh, M.
    Morisset, S.
    Detrait, M.
    Nicolini, F.
    Labussiere, H.
    Ducastelle, S.
    Barraco, F.
    Chelghoum, Y.
    Thomas, X.
    Wattel, E.
    Ranchon, F.
    Rioufol, C.
    HAEMATOLOGICA, 2012, 97 : 275 - 276
  • [27] Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia
    Xu, Xuezhu
    Liu, Rui
    Chen, Hongli
    Yang, Ruoyu
    Gao, Gongzhizi
    He, Aili
    Wang, Fangxia
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2025, 16
  • [28] The Use of 5-Azacitidine in Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience
    Martin Lopez, Ana A.
    Diez Campelo, Maria
    Rojas Porras, Silvia
    Redondo Guijo, Alba
    Lopez Corral, Lucia
    Sanchez Guijo, Fermin
    del Canizo, Consuelo
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S298 - S299
  • [29] The use of 5-azacitidine in allogeneic hematopoietic cell transplantation: A single center experience
    Diez Campelo, M.
    Martin, A. A.
    Rojas, S. M.
    Redondo, A.
    Labrador, J.
    Lopez-Corral, L.
    Sanchez-Guijo, F. M.
    Canizo, M. C.
    LEUKEMIA RESEARCH, 2013, 37 : S120 - S120
  • [30] High Throughput Pre-Clinical Models to Determine a Synergistic Molar Ratio of 5-Azacitidine to Venetoclax and Uncover Resistance Mechanisms to 5-Azacitidine and Venetoclax Combination Therapy in Acute Myeloid Leukemia
    Sarangdhar, Mithun Milind
    O'Brien, Eric
    VanCauwenbergh, Brett
    Alexander, Jackson
    Theile, Caroline
    Basu, Mitali
    Sarangdhar, Mayur
    Seibel, William
    Perentesis, John P.
    BLOOD, 2022, 140 : 10693 - 10694
12345